<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40742006</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2060</ISSN><JournalIssue CitedMedium="Internet"><Volume>57</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Annals of medicine</Title><ISOAbbreviation>Ann Med</ISOAbbreviation></Journal><ArticleTitle>A controlled comparative study of the effects of methotrexate and pharmacogenetic factors on arterial blood pressure and arterial stiffness in patients with rheumatoid arthritis.</ArticleTitle><Pagination><StartPage>2539311</StartPage><MedlinePgn>2539311</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2539311</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/07853890.2025.2539311</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Observational studies have shown that methotrexate, a conventional synthetic disease-modifying antirheumatic drug (csDMARD), is associated with lower arterial blood pressure (BP) and may reduce cardiovascular risk in rheumatoid arthritis (RA). However, it remains unclear whether a cause-and-effect relationship exists between the use of methotrexate and blood pressure reduction.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="UNASSIGNED">We conducted a controlled comparative study of treatment-na&#xef;ve newly diagnosed RA patients commenced on subcutaneous methotrexate (Group 1, <i>n</i>&#x2009;=&#x2009;31, age 57&#x2009;&#xb1;&#x2009;15&#x2009;years, 65% females, Disease Activity Score-28 - C-reactive protein, DAS28-CRP = 4.7&#x2009;&#xb1;&#x2009;1.2) or the DMARD comparator sulfasalazine (Group 2, <i>n</i>&#x2009;=&#x2009;31, 54&#x2009;&#xb1;&#x2009;17&#x2009;years, 61% females, DAS28-CRP = 5.0&#x2009;&#xb1;&#x2009;0.8). Clinic systolic (SBP, primary study endpoint) and diastolic BP (DBP) and augmentation index (AIx, a marker of arterial stiffness) were measured at baseline and after one and six months of treatment (ClinicalTrials.gov: NCT03254589).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">After six months, compared to Group 2, Group 1 patients had significantly lower SBP (-7.4&#x2009;mmHg, 95% CI -14.0 to -0.8, <i>p</i>&#x2009;=&#x2009;0.03). By contrast, there were no significant between-group differences in DBP (<i>p</i>&#x2009;=&#x2009;0.18), AIx (<i>p</i>&#x2009;=&#x2009;0.85), or DAS28-CRP (<i>p</i>&#x2009;=&#x2009;0.16). A significant effect of single nucleotide polymorphisms (SNPs) rs1801133 (methyl tetrahydrofolate reductase) and rs2231142 (ATP-binding cassette subfamily G member 2) on BP changes during methotrexate treatment was observed.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">This is the first comparative study showing that methotrexate significantly reduces SBP in RA. This effect did not coincide with significant changes in arterial stiffness or disease activity. Further research is warranted to investigate the mechanisms underpinning the SBP-lowering effects of methotrexate, the role of specific SNPs, and whether such effects may account for reduced cardiovascular risk in patients with RA.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mangoni</LastName><ForeName>Arduino A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0001-8699-1412</Identifier><AffiliationInfo><Affiliation>College of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University, Adelaide, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, Finders Medical Centre, Southern Adelaide Local Health Network, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiese</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0002-3255-9242</Identifier><AffiliationInfo><Affiliation>Centre for Pharmaceutical Innovation, Clinical &amp; Health Sciences, University of South Australia, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woodman</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-4094-1222</Identifier><AffiliationInfo><Affiliation>Centre for Epidemiology and Biostatistics, College of Medicine and Public Health, Flinders University, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sotgia</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3717-3437</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Sassari, Sassari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zinellu</LastName><ForeName>Angelo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8396-0968</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Sassari, Sassari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carru</LastName><ForeName>Ciriaco</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-6985-4907</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Sassari, Sassari, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Oncology Unit, University Hospital (AOUSS), Sassari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hulin</LastName><ForeName>Julie-Ann</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0003-4886-0416</Identifier><AffiliationInfo><Affiliation>College of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shanahan</LastName><ForeName>E Michael</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0001-8309-3289</Identifier><AffiliationInfo><Affiliation>College of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University, Adelaide, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, Flinders Medical Centre, Southern Adelaide Local Health Network, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tommasi</LastName><ForeName>Sara</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9449-2602</Identifier><AffiliationInfo><Affiliation>College of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University, Adelaide, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, Finders Medical Centre, Southern Adelaide Local Health Network, Adelaide, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03254589</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Med</MedlineTA><NlmUniqueID>8906388</NlmUniqueID><ISSNLinking>0785-3890</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.5.1.20</RegistryNumber><NameOfSubstance UI="D042965">Methylenetetrahydrofolate Reductase (NADPH2)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.5.1.20</RegistryNumber><NameOfSubstance UI="C573423">MTHFR protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>3XC8GUZ6CB</RegistryNumber><NameOfSubstance UI="D012460">Sulfasalazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="Y">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062186" MajorTopicYN="Y">Arterial Pressure</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="Y">Blood Pressure</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008727" MajorTopicYN="Y">Methotrexate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042965" MajorTopicYN="N">Methylenetetrahydrofolate Reductase (NADPH2)</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010597" MajorTopicYN="N">Pharmacogenetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012460" MajorTopicYN="N">Sulfasalazine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059289" MajorTopicYN="Y">Vascular Stiffness</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Methotrexate</Keyword><Keyword MajorTopicYN="N">atherosclerosis</Keyword><Keyword MajorTopicYN="N">blood pressure</Keyword><Keyword MajorTopicYN="N">cardiovascular disease</Keyword><Keyword MajorTopicYN="N">drug repositioning</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">pharmacogenetics</Keyword><Keyword MajorTopicYN="N">rheumatoid arthritis</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>31</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>31</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>31</Day><Hour>8</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40742006</ArticleId><ArticleId IdType="pmc">PMC12315184</ArticleId><ArticleId IdType="doi">10.1080/07853890.2025.2539311</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56. doi: 10.1038/s41572-019-0106-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0106-z</ArticleId><ArticleId IdType="pubmed">31420554</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf D, Ley K.. Immunity and inflammation in atherosclerosis. Circ Res. 2019;124(2):315&#x2013;327. doi: 10.1161/CIRCRESAHA.118.313591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.118.313591</ArticleId><ArticleId IdType="pmc">PMC6342482</ArticleId><ArticleId IdType="pubmed">30653442</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy P, Orecchioni M, Ley K.. How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. Nat Rev Immunol. 2022;22(4):251&#x2013;265. doi: 10.1038/s41577-021-00584-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00584-1</ArticleId><ArticleId IdType="pmc">PMC10111155</ArticleId><ArticleId IdType="pubmed">34389841</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Matteo A, Bathon JM, Emery P.. Rheumatoid arthritis. Lancet. 2023;402(10416):2019&#x2013;2033. doi: 10.1016/S0140-6736(23)01525-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)01525-8</ArticleId><ArticleId IdType="pubmed">38240831</ArticleId></ArticleIdList></Reference><Reference><Citation>Erre GL, Piga M, Fedele AL, et al. Prevalence and determinants of peripheral microvascular endothelial dysfunction in rheumatoid arthritis patients: a multicenter cross-sectional study. Mediators Inflamm. 2018;2018:6548715&#x2013;6548718. doi: 10.1155/2018/6548715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/6548715</ArticleId><ArticleId IdType="pmc">PMC5816852</ArticleId><ArticleId IdType="pubmed">29483841</ArticleId></ArticleIdList></Reference><Reference><Citation>Erre GL, Mangoni AA, Passiu G, et al. Comprehensive arginine metabolomics and peripheral vasodilatory capacity in rheumatoid arthritis: a monocentric cross-sectional study. Microvasc Res. 2020;131:104038. doi: 10.1016/j.mvr.2020.104038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mvr.2020.104038</ArticleId><ArticleId IdType="pubmed">32622695</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangoni AA, Tommasi S, Sotgia S, et al. Asymmetric dimethylarginine: a key player in the pathophysiology of endothelial dysfunction, vascular inflammation and atherosclerosis in rheumatoid arthritis? Curr Pharm Des. 2021;27(18):2131&#x2013;2140. doi: 10.2174/1381612827666210106144247.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612827666210106144247</ArticleId><ArticleId IdType="pubmed">33413061</ArticleId></ArticleIdList></Reference><Reference><Citation>van Sijl AM, Peters MJ, Knol DK, et al. Carotid intima media thickness in rheumatoid arthritis as compared to control subjects: a meta-analysis. Semin Arthritis Rheum. 2011;40(5):389&#x2013;397. doi: 10.1016/j.semarthrit.2010.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2010.06.006</ArticleId><ArticleId IdType="pubmed">20889191</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Huang L, Xu Q, et al. Assessment of aortic stiffness in patients with rheumatoid arthritis using pulse wave velocity: an update meta-analysis. Arch Med Res. 2019;50(7):401&#x2013;412. doi: 10.1016/j.arcmed.2019.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2019.10.010</ArticleId><ArticleId IdType="pubmed">31760330</ArticleId></ArticleIdList></Reference><Reference><Citation>Panoulas VF, Douglas KM, Milionis HJ, et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford). 2007;46(9):1477&#x2013;1482. doi: 10.1093/rheumatology/kem169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kem169</ArticleId><ArticleId IdType="pubmed">17704521</ArticleId></ArticleIdList></Reference><Reference><Citation>Panoulas VF, Metsios GS, Pace AV, et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford). 2008;47(9):1286&#x2013;1298. doi: 10.1093/rheumatology/ken159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ken159</ArticleId><ArticleId IdType="pubmed">18467370</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang X, Chou OHI, Cheung CL, et al. Is hypertension associated with arthritis? The United States national health and nutrition examination survey 1999-2018. Ann Med. 2022;54(1):1767&#x2013;1775. doi: 10.1080/07853890.2022.2089911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2089911</ArticleId><ArticleId IdType="pmc">PMC9258429</ArticleId><ArticleId IdType="pubmed">35786117</ArticleId></ArticleIdList></Reference><Reference><Citation>Milan A, Tosello F, Fabbri A, et al. Arterial stiffness: from physiology to clinical implications. High Blood Press Cardiovasc Prev. 2011;18(1):1&#x2013;12. doi: 10.2165/11588020-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11588020-000000000-00000</ArticleId><ArticleId IdType="pubmed">21612307</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutouyrie P, Chowienczyk P, Humphrey JD, et al. Arterial stiffness and cardiovascular risk in hypertension. Circ Res. 2021;128(7):864&#x2013;886. doi: 10.1161/CIRCRESAHA.121.318061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.121.318061</ArticleId><ArticleId IdType="pubmed">33793325</ArticleId></ArticleIdList></Reference><Reference><Citation>Chirinos JA, Segers P, Hughes T, et al. Large-artery stiffness in health and disease: JACC state-of-the-art review. J Am Coll Cardiol. 2019;74(9):1237&#x2013;1263. doi: 10.1016/j.jacc.2019.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2019.07.012</ArticleId><ArticleId IdType="pmc">PMC6719727</ArticleId><ArticleId IdType="pubmed">31466622</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson T, Rivolo S, Burkhoff D, et al. Physiological impact of afterload reduction on cardiac mechanics and coronary hemodynamics following isosorbide dinitrate administration in ischemic heart disease. J Cardiovasc Transl Res. 2021;14(5):962&#x2013;974. doi: 10.1007/s12265-021-10112-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12265-021-10112-0</ArticleId><ArticleId IdType="pmc">PMC8575737</ArticleId><ArticleId IdType="pubmed">33721195</ArticleId></ArticleIdList></Reference><Reference><Citation>Restivo V, Candiloro S, Daidone M, et al. Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus. Autoimmun Rev. 2022;21(1):102925. doi: 10.1016/j.autrev.2021.102925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102925</ArticleId><ArticleId IdType="pubmed">34454117</ArticleId></ArticleIdList></Reference><Reference><Citation>Baghdadi LR, Woodman RJ, Shanahan EM, et al. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One. 2015;10(2):e0117952. doi: 10.1371/journal.pone.0117952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0117952</ArticleId><ArticleId IdType="pmc">PMC4331556</ArticleId><ArticleId IdType="pubmed">25689371</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos-Moreno P, Rodriguez-Vargas GS, Martinez S, et al. Metabolic abnormalities, cardiovascular disease, and metabolic syndrome in adult rheumatoid arthritis patients: current perspectives and clinical implications. Open Access Rheumatol. 2022;14:255&#x2013;267. doi: 10.2147/OARRR.S285407.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OARRR.S285407</ArticleId><ArticleId IdType="pmc">PMC9642585</ArticleId><ArticleId IdType="pubmed">36388145</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong P, Cui ZY, Huang XF, et al. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct Target Ther. 2022;7(1):131. doi: 10.1038/s41392-022-00955-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00955-7</ArticleId><ArticleId IdType="pmc">PMC9033871</ArticleId><ArticleId IdType="pubmed">35459215</ArticleId></ArticleIdList></Reference><Reference><Citation>Soehnlein O, Libby P.. Targeting inflammation in atherosclerosis &#x2013; from experimental insights to the clinic. Nat Rev Drug Discov. 2021;20(8):589&#x2013;610. doi: 10.1038/s41573-021-00198-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-021-00198-1</ArticleId><ArticleId IdType="pmc">PMC8112476</ArticleId><ArticleId IdType="pubmed">33976384</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelen SE, Robinson AJB, Zurke YX, et al. Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed? Nat Rev Cardiol. 2022;19(8):522&#x2013;542. doi: 10.1038/s41569-021-00668-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-021-00668-4</ArticleId><ArticleId IdType="pmc">PMC8802279</ArticleId><ArticleId IdType="pubmed">35102320</ArticleId></ArticleIdList></Reference><Reference><Citation>Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41&#x2013;58. doi: 10.1038/nrd.2018.168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2018.168</ArticleId><ArticleId IdType="pubmed">30310233</ArticleId></ArticleIdList></Reference><Reference><Citation>Parvathaneni V, Kulkarni NS, Muth A, et al. Drug repurposing: a promising tool to accelerate the drug discovery process. Drug Discov Today. 2019;24(10):2076&#x2013;2085. doi: 10.1016/j.drudis.2019.06.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2019.06.014</ArticleId><ArticleId IdType="pmc">PMC11920972</ArticleId><ArticleId IdType="pubmed">31238113</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez L, Bulnes JF, Orellana MP, et al. The role of colchicine in atherosclerosis: from bench to bedside. Pharmaceutics. 2022;14(7):1395. doi: 10.3390/pharmaceutics14071395.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14071395</ArticleId><ArticleId IdType="pmc">PMC9323936</ArticleId><ArticleId IdType="pubmed">35890291</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedoui Y, Guillot X, S&#xe9;lambarom J, et al. Methotrexate an old drug with new tricks. Int J Mol Sci. 2019;20(20):5023. doi: 10.3390/ijms20205023.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20205023</ArticleId><ArticleId IdType="pmc">PMC6834162</ArticleId><ArticleId IdType="pubmed">31658782</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronstein BN, Aune TM.. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020;16(3):145&#x2013;154. doi: 10.1038/s41584-020-0373-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0373-9</ArticleId><ArticleId IdType="pubmed">32066940</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilsdon TD, Whittle SL, Thynne TR, et al. Methotrexate for psoriatic arthritis. Cochrane Database Syst Rev. 2019;1(1):CD012722. doi: 10.1002/14651858.CD012722.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD012722.pub2</ArticleId><ArticleId IdType="pmc">PMC6353064</ArticleId><ArticleId IdType="pubmed">30656673</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Xiao L, Zhu J, et al. Methotrexate use reduces mortality risk in rheumatoid arthritis: a systematic review and meta-analysis of cohort studies. Semin Arthritis Rheum. 2022;55:152031. doi: 10.1016/j.semarthrit.2022.152031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2022.152031</ArticleId><ArticleId IdType="pubmed">35671648</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun KJ, Liu LL, Hu JH, et al. Methotrexate can prevent cardiovascular events in patients with rheumatoid arthritis: an updated meta-analysis. Medicine (Baltimore). 2021;100(7):e24579. doi: 10.1097/MD.0000000000024579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000024579</ArticleId><ArticleId IdType="pmc">PMC7899830</ArticleId><ArticleId IdType="pubmed">33607787</ArticleId></ArticleIdList></Reference><Reference><Citation>Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480&#x2013;489. doi: 10.1136/annrheumdis-2014-206624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-206624</ArticleId><ArticleId IdType="pmc">PMC4345910</ArticleId><ArticleId IdType="pubmed">25561362</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie F, Chen L, Yun H, et al. Benefits of methotrexate use on cardiovascular disease risk among rheumatoid arthritis patients initiating biologic disease-modifying antirheumatic drugs. J Rheumatol. 2021;48(6):804&#x2013;812. doi: 10.3899/jrheum.191326.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.191326</ArticleId><ArticleId IdType="pubmed">33060309</ArticleId></ArticleIdList></Reference><Reference><Citation>Sendaydiego X, Gold LS, Dubreuil M, et al. Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis. Rheumatology (Oxford). 2025;64(6):3434&#x2013;3443. doi: 10.1093/rheumatology/keaf096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaf096</ArticleId><ArticleId IdType="pmc">PMC12107039</ArticleId><ArticleId IdType="pubmed">39936579</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangoni AA, Sotgia S, Zinellu A, et al. Methotrexate and cardiovascular prevention: an appraisal of the current evidence. Ther Adv Cardiovasc Dis. 2023;17:17539447231215213. doi: 10.1177/17539447231215213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17539447231215213</ArticleId><ArticleId IdType="pmc">PMC10732001</ArticleId><ArticleId IdType="pubmed">38115784</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker JF, Sauer B, Teng CC, et al. Initiation of disease-modifying therapies in rheumatoid arthritis is associated with changes in blood pressure. J Clin Rheumatol. 2018;24(4):203&#x2013;209. doi: 10.1097/RHU.0000000000000736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0000000000000736</ArticleId><ArticleId IdType="pmc">PMC7461421</ArticleId><ArticleId IdType="pubmed">29664818</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangoni AA, Baghdadi LR, Shanahan EM, et al. Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study. Ther Adv Musculoskelet Dis. 2017;9(9):213&#x2013;229. doi: 10.1177/1759720X17719850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1759720X17719850</ArticleId><ArticleId IdType="pmc">PMC5600310</ArticleId><ArticleId IdType="pubmed">28932292</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodman RJ, Baghdadi LR, Shanahan ME, et al. The temporal relationship between arterial stiffening and blood pressure is modified by methotrexate treatment in patients with rheumatoid arthritis. Front Physiol. 2017;8:593. doi: 10.3389/fphys.2017.00593.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2017.00593</ArticleId><ArticleId IdType="pmc">PMC5559508</ArticleId><ArticleId IdType="pubmed">28861004</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadwen B, Stranges S, Barra L.. Risk factors for hypertension in rheumatoid arthritis patients-a systematic review. Autoimmun Rev. 2021;20(4):102786. doi: 10.1016/j.autrev.2021.102786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102786</ArticleId><ArticleId IdType="pubmed">33609791</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangoni AA, Wiese MD, Woodman RJ, et al. Methotrexate, blood pressure and arterial function in rheumatoid arthritis: study protocol. Future Cardiol. 2024;20(13):671&#x2013;683. doi: 10.1080/14796678.2024.2411167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14796678.2024.2411167</ArticleId><ArticleId IdType="pmc">PMC11552479</ArticleId><ArticleId IdType="pubmed">39387403</ArticleId></ArticleIdList></Reference><Reference><Citation>Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580&#x2013;1588. doi: 10.1136/ard.2010.138461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.138461</ArticleId><ArticleId IdType="pubmed">20699241</ArticleId></ArticleIdList></Reference><Reference><Citation>Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569&#x2013;2581. doi: 10.1002/art.27584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27584</ArticleId><ArticleId IdType="pubmed">20872595</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz KF, Altman DG, Moher D.. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8(1):18. doi: 10.1186/1741-7015-8-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-8-18</ArticleId><ArticleId IdType="pmc">PMC2860339</ArticleId><ArticleId IdType="pubmed">20334633</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med. 1994;121(11):833&#x2013;841. doi: 10.7326/0003-4819-121-11-199412010-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-121-11-199412010-00002</ArticleId><ArticleId IdType="pubmed">7978695</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y. Subcutaneous injection of methotrexate: advantages in the treatment of rheumatoid arthritis. Mod Rheumatol. 2023;33(4):633&#x2013;639. doi: 10.1093/mr/roac156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/mr/roac156</ArticleId><ArticleId IdType="pubmed">36525530</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabit CE, Holbrook M, Shenouda SM, et al. Effect of sulfasalazine on inflammation and endothelial function in patients with established coronary artery disease. Vasc Med. 2012;17(2):101&#x2013;107. doi: 10.1177/1358863X12440117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1358863X12440117</ArticleId><ArticleId IdType="pmc">PMC3632403</ArticleId><ArticleId IdType="pubmed">22496207</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols WW, Singh BM.. Augmentation index as a measure of peripheral vascular disease state. Curr Opin Cardiol. 2002;17(5):543&#x2013;551. doi: 10.1097/00001573-200209000-00016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001573-200209000-00016</ArticleId><ArticleId IdType="pubmed">12357133</ArticleId></ArticleIdList></Reference><Reference><Citation>van Riel PL, Renskers L.. The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(5 Suppl 101):S40&#x2013;S44.</Citation><ArticleIdList><ArticleId IdType="pubmed">27762189</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue E, Yamanaka H, Hara M, et al. Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis. 2007;66(3):407&#x2013;409. doi: 10.1136/ard.2006.054205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2006.054205</ArticleId><ArticleId IdType="pmc">PMC1856019</ArticleId><ArticleId IdType="pubmed">16926186</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikiphorou E, Radner H, Chatzidionysiou K, et al. Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. Arthritis Res Ther. 2016;18(1):251. doi: 10.1186/s13075-016-1151-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-016-1151-6</ArticleId><ArticleId IdType="pmc">PMC5086038</ArticleId><ArticleId IdType="pubmed">27793211</ArticleId></ArticleIdList></Reference><Reference><Citation>Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334&#x2013;1357. doi: 10.1161/HYPERTENSIONAHA.120.15026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.120.15026</ArticleId><ArticleId IdType="pubmed">32370572</ArticleId></ArticleIdList></Reference><Reference><Citation>Butlin M, Qasem A.. Large artery stiffness assessment using SphygmoCor technology. Pulse (Basel). 2017;4(4):180&#x2013;192. doi: 10.1159/000452448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000452448</ArticleId><ArticleId IdType="pmc">PMC5290450</ArticleId><ArticleId IdType="pubmed">28229053</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh S, Collie-Duguid ES, Li T, et al. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics. 1999;58(3):310&#x2013;312. doi: 10.1006/geno.1999.5833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/geno.1999.5833</ArticleId><ArticleId IdType="pubmed">10373329</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauritz R, Giovannetti E, Beumer IJ, et al. Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer. Clin Colorectal Cancer. 2009;8(3):146&#x2013;154. doi: 10.3816/CCC.2009.n.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3816/CCC.2009.n.024</ArticleId><ArticleId IdType="pubmed">19632929</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreson R, Puurand T, Remm M.. SNPmasker: automatic masking of SNPs and repeats across eukaryotic genomes. Nucleic Acids Res. 2006;34(Web Server issue):W651&#x2013;5. doi: 10.1093/nar/gkl125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkl125</ArticleId><ArticleId IdType="pmc">PMC1538889</ArticleId><ArticleId IdType="pubmed">16845091</ArticleId></ArticleIdList></Reference><Reference><Citation>Phan L, Jin Y, Zhang H, et al. 
ALFA: allele frequency aggregator. Bethesda, MD: National Center for Biotechnology Information, U.S. National Library of Medicine; 2020. www.ncbi.nlm.nih.gov/snp/docs/gsr/alfa/</Citation></Reference><Reference><Citation>Johnson TM, Sayles HR, Baker JF, et al. Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis. Ann Rheum Dis. 2021;80(11):1385&#x2013;1392. doi: 10.1136/annrheumdis-2021-220125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220125</ArticleId><ArticleId IdType="pmc">PMC8516691</ArticleId><ArticleId IdType="pubmed">34049859</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurent S, Boutouyrie P.. The structural factor of hypertension: large and small artery alterations. Circ Res. 2015;116(6):1007&#x2013;1021. doi: 10.1161/CIRCRESAHA.116.303596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.116.303596</ArticleId><ArticleId IdType="pubmed">25767286</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y, Wu L, Zhuang W.. Methylenetetrahydrofolate reductase gene rs1801133 and rs1801131 polymorphisms and essential hypertension risk: a comprehensive analysis. Cardiovasc Ther. 2022;2022:2144443&#x2013;2144418. doi: 10.1155/2022/2144443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/2144443</ArticleId><ArticleId IdType="pmc">PMC8888071</ArticleId><ArticleId IdType="pubmed">35284002</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41(6):1183&#x2013;1190. doi: 10.1161/01.HYP.0000069700.62727.C5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.HYP.0000069700.62727.C5</ArticleId><ArticleId IdType="pubmed">12707287</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Spencer KL, Voruganti VS, et al. Association of functional polymorphism rs2231142 (Q141K) in the ABCG2 gene with serum uric acid and gout in 4&#x2009;US populations: the PAGE Study. Am J Epidemiol. 2013;177(9):923&#x2013;932. doi: 10.1093/aje/kws330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kws330</ArticleId><ArticleId IdType="pmc">PMC4023295</ArticleId><ArticleId IdType="pubmed">23552988</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood pressure lowering treatment trialists C. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397:1625&#x2013;1636. doi: 10.1016/S0140-6736(21)00590-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00590-0</ArticleId><ArticleId IdType="pmc">PMC8102467</ArticleId><ArticleId IdType="pubmed">33933205</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui J, Ridker PM, Solomon DH.. Blood pressure changes during methotrexate treatment: results from a randomized placebo-controlled trial among patients with cardiovascular risk. Rheumatology (Oxford). 2025;64(6):3917&#x2013;3920. doi: 10.1093/rheumatology/keae604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keae604</ArticleId><ArticleId IdType="pmc">PMC12107077</ArticleId><ArticleId IdType="pubmed">39657237</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangoni AA, Sherwood RA, Asonganyi B, et al. Short-term oral folic acid supplementation enhances endothelial function in patients with type 2 diabetes. Am J Hypertens. 2005;18(2&#x2009;Pt 1):220&#x2013;226. doi: 10.1016/j.amjhyper.2004.08.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjhyper.2004.08.036</ArticleId><ArticleId IdType="pubmed">15752950</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo Y, Li J, Qin X, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA. 2015;313(13):1325&#x2013;1335. doi: 10.1001/jama.2015.2274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.2274</ArticleId><ArticleId IdType="pubmed">25771069</ArticleId></ArticleIdList></Reference><Reference><Citation>Asbaghi O, Salehpour S, Rezaei Kelishadi M, et al. Folic acid supplementation and blood pressure: a GRADE-assessed systematic review and dose-response meta-analysis of 41,633 participants. Crit Rev Food Sci Nutr. 2023;63(13):1846&#x2013;1861. doi: 10.1080/10408398.2021.1968787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10408398.2021.1968787</ArticleId><ArticleId IdType="pubmed">34478339</ArticleId></ArticleIdList></Reference><Reference><Citation>Mebrahtu TF, Morgan AW, West RM, et al. Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: a population-based cohort study. CMAJ. 2020;192(12):E295&#x2013;E301. doi: 10.1503/cmaj.191012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.191012</ArticleId><ArticleId IdType="pmc">PMC7101178</ArticleId><ArticleId IdType="pubmed">32392512</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson AG, Nguyen TV, Day RO.. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121(4):289&#x2013;300. doi: 10.7326/0003-4819-121-4-199408150-00011.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-121-4-199408150-00011</ArticleId><ArticleId IdType="pubmed">8037411</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomides APM, Albuquerque CP, Santos ABV, et al. High levels of polypharmacy in rheumatoid arthritis-a challenge not covered by current management recommendations: data from a large real-life study. J Pharm Pract. 2021;34(3):365&#x2013;371. doi: 10.1177/0897190019869158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0897190019869158</ArticleId><ArticleId IdType="pubmed">31451091</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyake H, Sada RM, Akebo H, et al. Prevalence and factors associated with polypharmacy among patients with rheumatoid arthritis: a single-centre, cross-sectional study. Clin Rheumatol. 2023;42(9):2287&#x2013;2295. doi: 10.1007/s10067-023-06646-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-023-06646-0</ArticleId><ArticleId IdType="pubmed">37243802</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>